BioSpace News Archive

Nordic Nanovector ASA announces that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company’s Annual General Meeting on 28 April 2022.

Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA -based therapeutics for patients with cardiac diseases, announced the appointment of Dr. Russell Greig, as independent Chairman of its Board of Directors.

BeiGene, Ltd. announced that marketing authorization applications for tislelizumab, submitted by Novartis, the license holder in Europe, have been validated for regulatory review by the European Medicines Agency for patients with advanced or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy and for patients with non-small cell lung cancers.

On 5 April 2022, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2021.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.

Theravance Biopharma, Inc. will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET.

United Therapeutics Corporation, a public benefit corporation, announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ in patients with pulmonary arterial hypertension in the journal Pulmonary Circulation.

In a new article appearing in the current issue of the Cell Press scientific journal iScience, AntiCancer Inc. of San Diego has demonstrated that the addiction of cancer to the common amino acid methionine is the basis of the malignancy of cancer.

RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced preliminary first quarter 2022 net product sales of UPNEEQ®, 0.1%, the first and only U.S. Food and Drug Administration - approved ophthalmic solution for blepharoptosis, or droopy eyelid, of $5.9 million.